Epidermal chemokines and modulation by antihistamines, antibiotics and antifungals

Experimental Dermatology

Volumn 17, Issue 2, 2008, Pages 81-90

  Tokura, Yoshiki ^a   Kobayashi, Miwa ^a   Kabashima, Kenji ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Antibiotic; Antifungal; Antihistamine; Chemokine; Epidermis

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETOTASTINE; CETIRIZINE; CHEMOKINE; CLARITHROMYCIN; CXCL9 CHEMOKINE; DESLORATADINE; EPINASTINE; FEXOFENADINE; GAMMA INTERFERON; GRISEOFULVIN; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; KETOCONAZOLE; LEVOCETIRIZINE; LIRANAFTATE; LORATADINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NADIFLOXACIN; OLOPATADINE; RANTES; ROXITHROMYCIN; TERBINAFINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CONTACT DERMATITIS; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; DRUG TISSUE LEVEL; EPIDERMIS; EPIDERMIS CELL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KERATINOCYTE; LICHEN PLANUS; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; NONHUMAN; OPTIMAL DRUG DOSE; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS REGULATION; PSORIASIS; REVIEW; SKIN ALLERGY; SKIN INFLAMMATION; SKIN SENSITIVITY; TH1 CELL; TH2 CELL; TINEA PEDIS; URTICARIA;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CHEMOKINES; EPIDERMIS; HISTAMINE H1 ANTAGONISTS; HUMANS; KERATINOCYTES; SKIN DISEASES;

EID: 38349061025     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00657.x     Document Type: Review

References (88)

1. Xu H, Bjarnason B, Elmets C A. Sensitization versus elicitation in allergic contact dermatitis: Potential differences at cellular and molecular levels. Am J Contact Dermat 2000: 11: 228-234.
2. Pastore S, Mascia F, Mariotti F, Dattilo C, Girolomoni G. Chemokine networks in inflammatory skin diseases. Eur J Dermatol 2004: 14: 203-208.
3. Homey B, Steinhoff M, Ruzicka T, Leung D Y. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006: 118: 178-189.
4. + lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 2000: 115: 640-646.
5. Boorsma D M, Flier J, Sampat S, et al. Chemokine IP-10 expression in cultured human keratinocytes. Arch Dermatol Res 1998: 290: 335-341.
6. Xiao T, Kagami S, Saeki H, et al. Both IL-4 and IL-13 inhibit the TNF-α and IFN-γ enhanced MDC production in a human keratinocyte cell line, HaCaT cells. J Dermatol Sci 2003: 31: 111-117.
7. Albanesi C, Scarponi C, Sebastiani S, et al. IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. J Immunol 2000: 165: 1395-1402.
8. Hino R, Shimauchi T, Tokura Y. Treatment with IFN-γ increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides. J Dermatol Sci 2005: 38: 189-195.
9. Benoit S, Toksoy A, Brocker E B, Gillitzer R, Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: Effective reduction of chemokine expression. Br J Dermatol 2004: 150: 1009-1012.
10. Hino R, Kobayashi M, Mori T, et al. Inhibition of T helper 2 chemokine production by narrowband ultraviolet B in cultured keratinocytes. Br J Dermatol 2007: 156: 830-837.
11. Kobayashi M, Shimauchi T, Hino R, Tokura Y. Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: Its dual inhibitory effects on the ligands and the receptors. Cell Immunol 2004: 228: 27-33.
12. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000: 18: 217-242.
13. + T cells in IP-10 expression. J Dermatol Sci 2002: 28: 234-241.
14. Schroder J M, Reich K, Kabashima K, et al. Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes? Exp Dermatol 2006: 15: 913-929.
15. Flier J, Boorsma D M, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001: 194: 398-405.
16. Rottman J B, Smith T L, Ganley K G, Kikuchi T, Krueger J G. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001: 81: 335-347.
17. Fukuoka M, Ogino Y, Sato H, et al. RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Br J Dermatol 1998: 138: 63-70.
18. Albanesi C, Scarponi C, Sebastiani S, et al. A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases. J Leuk Biol 2001: 70: 617-623.
19. Fujita H, Asahina A, Sugaya M, et al. Differential production of Th1- and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells. J Invest Dermatol 2005: 124: 343-350.
20. Xiao T, Fujita H, Saeki H, et al. Thymus and activation-regulated chemokine (TARC/CCL17) produced by mouse epidermal Langerhans cells is upregulated by TNF-α and IL-4 and downregulated by IFN-γ. Cytokine 2003: 23: 126-132.
21. Mitsui H, Watanabe T, Saeki H, et al. Differential expression and function of Toll-like receptors in Langerhans cells: Comparison with splenic dendritic cells. J Invest Dermatol 2004: 122: 95-102.
22. Annels N E, Da Costa C E, Prins F A, Willemze A, Hogendoorn P C, Egeler R M. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med 2003: 197: 1385-1390.
23. Sallusto F, Lenig D, Mackay C R, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998: 187: 875-883.
24. Kagami S, Saeki H, Komine M, et al. CCL28 production in HaCaT cells was mediated by different signal pathways from CCL27. Exp Dermatol 2006: 15: 95-100.
25. Tsuda T, Tohyama M, Yamasaki K, et al. Lack of evidence for TARC/CCL17 production by normal human keratinocytes in vitro. J Dermatol Sci 2003: 31: 37-42.
26. Moed H, Boorsma D M, Tensen C P, et al. Increased CCL27-CCR10 expression in allergic contact dermatitis: Implications for local skin immunity. J Pathol 2004: 204: 39-46.
27. +T cells display distinct migratory responses to chemokines produced during allergic contact dermatitis. J Invest Dermatol 2002: 118: 1052-1058.
28. Homey B Chemokines and inflammatory skin diseases. In: Advances in Dermatology, Vol. 21. New York: Mosby Inc., 2005: 251-277.
29. Wang B, Feliciani C, Freed I, Cai Q, Sauder D N. Insights into molecular mechanisms of contact hypersensitivity gained from gene knockout studies. J Leuk Biol 2001: 70: 185-191.
30. Kissenpfennig A, Henri S, Dubois B, et al. Dynamics and function of Langerhans cells in vivo: Dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005: 22: 643-654.
31. Kaplan D H, Jenison M C, Saeland S, et al. Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005: 23: 611-620.
32. Barker J N W N, Mitra R S, Griffiths C E M, Dixit V M, Nickoloff B J. Keratinocytes as initiators of inflammation. Lancet 1991: 337: 211-214.
33. Enk A H, Katz S I. Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 1992: 89: 1389-1402.
34. Gautam S, Battisto J, Major J A, Armstrong D, Stoler M, Hamilton T A. Chemokine expression in trinitrochlorobenzene-mediated contact hypersensitivity. J Leuk Biol 1994: 55: 452-460.
35. Tensen C P, Flier J, Rampersad S S, et al. Genomic organization, sequence and transcriptional regulation of the human CXCL 11 gene. Biochem Biophys Acta 1999: 1446: 167-172.
36. Flier J, Boorsma D M, Bruynzeel D P, et al. The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol 1999: 113: 574-578.
37. Kaplan G, Luster A D, Hancock G, Cohn Z A. The expression of a γ interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med 1987: 166: 1098-1108.
38. Tensen C P, Vermeer M H, van der Stoop P M, et al. Epidermal interferon-γ inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. J Invest Dermatol 1998: 111: 222-226.
39. Wang B, Fujisawa H, Zhuang L, et al. CD4+ Th1 and CD8+ type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity. J Immunol 2000: 165: 6783-6790.
40. Xu H, DiIulio N A, Fairchild R L. T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: Interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (Il) 4/Il-10-producing (Th2) negative regulatory CD4+ T cells. J Exp Med 1996: 183: 1001-1012.
41. Dubois B, Chapat L, Goubier A, Papiernik M, Nicolas J F, Kaiserlian D. Innate CD4+ CD25+ regulatory T cells are required for oral tolerance and inhibition of CD8+ T cells mediating skin inflammation. Blood 2003: 102: 3295-3301.
42. Imai S, Atarashi K, Ikesue K, Akiyama K, Tokura Y. Establishment of murine model of allergic photocontact dermatitis to ketoprofen and characterization of pathogenic T cells. J Dermatol Sci 2006: 41: 127-136.
43. Suzuki K, Yamazaki S, Tokura Y. Expression of T-cell cytokines in challenged skin of murine allergic contact photosensitivity: Low responsiveness is associated with induction of Th2 cytokines. J Dermatol Sci 2000: 23: 138-144.
44. Amon U, Gibbs B F, Buss G, Nitschke M. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm Res 2000: 49: 112-116.
45. Kabashima K, Shiraishi N, Sugita K, et al. CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol 2007: 171: 1249-1257.
46. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003: 148: 1212-1221.
47. Ito J, Asano K, Tryka E, et al. Suppressive effects of co-stimulatory molecule expressions on mouse splenocytes by anti-allergic agents in vitro. Mediators Inflamm 2000: 9: 69-75.
48. Matsukura M, Yajima A, Yamazaki F, et al. Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis. Skin Pharmacol Appl Skin Physiol 2003: 16: 405-410.
49. Vignola A M, Crampette L, Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995: 50: 200-203.
50. Albanesi C, Pastore S, Fanales-Belasio E, Girolomoni G. Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes. Clin Exp Allergy 1998: 28: 101-109.
51. Izu K, Tokura Y. The various effects of four H1-antagonists on serum substance P levels in patients with atopic dermatitis. J Dermatol 2005: 32: 776-781.
52. Kobayashi M, Kabashima K, Tokura Y. Inhibitory effects of epinastine on chemokine production and MHC class II/CD54 expression in keratinocytes. J Dermatol Sci 2007: 45: 144-146.
53. Kobayashi M, Tokura Y. Preferential downmodulation of certain chemokines by fexofenadine in human keratinocytes. J Dermatol Sci 2005: 38: 67-69.
54. Bruno G, Andreozzi P, Graf U, et al. Cetirizine, a second-generation H1 antagonist, modulates Rantes and MCP-1 levels in allergic rhinitis. Int J Immunopathol Pharmacol 2002: 15: 113-118.
55. Ikemura T, Okarmura K, Sasaki Y, Ishi H, Ohmori K. KW-4679-induced inhibition of tachykininergic contraction in the guinea-pig bronchi by prejunctional inhibition of peripheral sensory nerves. Br J Pharmacol 1996: 118: 1565-1573.
56. Tokura Y, Kobayashi M, Ito T, Takahashi H, Matsubara A, Takigawa M. Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells. Cell Immunol 2003: 224: 47-54.
57. Furukawa H, Takahashi M, Nakamura K, Kaneko F. Effect of an antiallergic drug (olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. J Dermatol Sci 2004: 36: 165-172.
58. Tasaka K. Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today 2000: 36: 735-757.
59. Masutani M, Ueda H, Takeuchi M, et al. Clinical study of WAL801CL on psoriasis vulgaris with pruritus. J Clin Ther Med 1992: 8 (Suppl.1): 87-95.
60. Leurs R, Church M K, Taglialatela M. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002: 32: 489-498.
61. Bakker R A, Wieland K, Timmerman H, Leurs R. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur J Pharmacol 2000: 387: R5-7.
62. Wu R L, Anthes J C, Kreutner W, Harris A G, West R E. Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 receptor. Int Arch Allergy Immunol 2004: 135: 313-318.
63. Bakker R A, Schoonus S B, Smit M J, Timmerman H, Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: Roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001: 60: 1133-1142.
64. Kanda N, Shimizu T, Tada Y, Watanabe S. IL-18 enhances IFN-γ-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol 2007: 37: 338-350.
65. Shinkai M, Foster G H, Rubin B K. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006: 290: L75-L85.
66. Abeyama K, Kawahara K, Iino S, et al. Antibiotic cyclic AMP signaling by 'primed' leukocytes confers anti-inflammatory cytoprotection. J Leuk Biol 2003: 74: 908-915.
67. Sugiyama K, Shirai R, Mukae H, et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol 2007: 147: 540-546.
68. Ohshima A, Tokura Y, Wakita H, Furukawa F, Takigawa M. Roxithromycin down-modulates antigen-presenting and interleukin-1β-producing abilities of murine Langerhans cells. J Dermatol Sci 1998: 17: 214-222.
69. Tsai W C, Rodriguez M L, Young K S, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004: 170: 1331-1339.
70. Wakita H, Tokura Y, Furukawa F, Takigawa M. The macrolide antibiotic, roxithromycin suppresses IFN-γ-mediated immunological functions of cultured normal human keratinocytes. Biol Pharm Bull 1996: 19: 224-227.
71. + cell changes in psoriasis associated with roxithromycin-induced clinical improvement. Eur J Dermatol 2001: 11: 410-415.
72. Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol 2000: 27: 508-512.
73. Tokura Y, Sugaya K, Kageyama H, et al. Inhibitory effect of roxithromycin on the myeloperoxidase activity of peripheral polymorphonuclear leukocytes: Its evaluation in patients with psoriasis and pustulosis palmaris et plantaris. Jpn J Inflammation 1995: 15: 461-465.
74. Ohmori Y, Schreiber R D, Hamilton T A. Synergy between interferon-γ and tumor necrosis factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB. J Biol Chem 1997: 272: 14899-14907.
75. Komine M, Kakinuma T, Kagami S, Hanakawa Y, Hashimoto K, Tamaki. Mechanism of thymus- and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycin. J Invest Dermatol 2005: 125: 491-498.
76. Kuwahara K, Kitazawa T, Kitagaki H, Tsukamoto T, Kikuchi M. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci 2005: 38: 47-55.
77. Murata K, Sugita K, Kobayashi M, Kabashima K, Tokura Y. Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes. J Dermatol Sci 2006: 42: 91-99.
78. Sehgal V N, Abraham G J, Malik G B. Griseofulvin therapy in lichen planus. A double-blind controlled trial. Br J Dermatol 1972: 87: 383-385.
79. Back O, Scheynius A, Johansson S G. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res 1995: 287: 448-451.
80. Ford G P, Farr P M, Ive F A, Shuster S. The response of seborrheic dermatitis to ketoconazole. Br J Dermatol 1984: 111: 603-607.
81. Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen P A. The antiinflammatory effects of ketoconazole. A comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea pigs. J Am Acad Dermatol 1991: 25: 257-261.
82. Beetens J R, Loots W, Somers Y, Coene M C, De Clerck F. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol 1986: 35: 883-891.
83. Sugita T, Tajima M, Ito T, Saito M, Tsuboi R, Nishikawa A. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 2005: 43: 2824-2829.
84. Kanda N, Watanabe S. Suppressive effects of antimycotics on tumor necrosis factor-α-induced CCL27, CCL2, and CCL5 production in human keratinocytes. Biochem Pharmacol 2006: 72: 463-473.
85. Friccius H, Pohla H, Adibzadeh M, Siegels-Hubenthal P, Schenk A, Pawelec G. The effects of the antifungal azole itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells. Int J Immunopharmacol 1992: 14: 791-799.
86. Koga T, Ishizaki H, Matsumoto T, Toshitani S. Enhanced release of interleukin-8 from human epidermal keratinocytes in response to stimulation with trichophytin in vitro. Acta Derm Venereol 1996: 76: 399-400.
87. Oku Y, Sakuma K, Yokoyama K, Miyaji M. Fungal activity of liranaftate against Trichophyton rubrum. Jpn J Med Mycol 2002: 43: 181-187.
88. Gantner B N, Simmons R M, Canavera S J, Akira S, Underhill D M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003: 197: 1107-1117.